Long-lasting complete response to SHR-1701 plus famitinib in refractory advanced gallbladder cancer: A case report

Volume 19, Issue 3, December 2023 .

Source: Human Vaccines and Immunotherapeutics - December 21, 2023 Category: Allergy & Immunology Authors: Lixia YiXiaoyan ZhuJing XieZhiqiang Menga Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, Chinab Department of Minimally Invasive Therapy Center, Fudan University Shanghai Cancer Center, Shanghai, Chinac Department o Source Type: research